What is SWK Holdings Corporation (SWKH)?

SWK Holdings Corporation (SWKH) is a stock in the Financial Services sector, Asset Management industry. View full analysis on Stocks360.

What is the current price of SWKH?

The current price of SWKH is $15.90. Prices are updated in real time on Stocks360.

What is SWKH's price-to-earnings (PE) ratio?

SWKH's trailing twelve-month PE ratio is -27.41, based on current price and earnings per share data available on Stocks360.

What is SWKH's market capitalization?

SWKH's market capitalization is $192,326,066.00, placing it in the small-cap tier.

Does SWKH pay a dividend?

Yes. SWKH has a trailing twelve-month dividend yield of 0.25%. Dividend data is sourced from financial market providers and displayed on Stocks360.

SWK Holdings Corporation (SWKH)

Stock analysis · NASDAQ · Financial Services · Asset Management

$15.90

Market Cap

$192.33M

PE (TTM)

-27.41

EPS (TTM)

N/A

Dividend Yield

25.16%

Beta

0.30

Day Range

$15.90 – $15.90

52-wk Range

$12.54 – $17.90

Avg Volume

N/A

Volume

105.55K

SWK Holdings Corporation (SWKH) is a publicly traded company in the Financial Services sector. Latest price: $15.90. Market cap $192.33M. Trailing PE -27.41. Dividend yield 25.16%. Sign in to Stocks360 for full DCF valuation, fundamentals, technicals, and AI-driven analysis.

Get full analysis → Short-Term Analysis →

1-Year Price

2025-10-30 · $16.15 2026-04-15 · $15.90 (-1.55%)

Earnings

Most Recent

Mar 20, 2026

EPS $-1.59 vs est. $0.53

Missed by $2.12

Proprietary Signals

Signal snapshot temporarily unavailable.

About SWK Holdings Corporation

SWK Holdings Corporation (SWKH) operates as a specialized financial institution, primarily concentrating its efforts within the healthcare sector. The company's operations are distinctly divided into two core segments: Finance Receivables and Pharmaceutical Development. Within its finance division, SWK offers bespoke funding solutions tailored to a diverse array of life science enterprises. These include companies spanning biotechnology, medical devices, diagnostic tools, animal health, and pharmaceuticals, alongside various institutions and individual innovators. Furthermore, the company extends non-discretionary investment advisory services, managing separate accounts for institutional clients keen on investing in the life science finance domain. Its Pharmaceutical Development segment involves the creation, formulation, production, and licensing of pharmaceutical products, leveraging its proprietary Peptelligence platform. A key strategic objective here is to license its internally developed product pipeline to external partners, aiming to generate innovative formulations through its unique technology, ultimately designed to benefit patients and their caregivers. Founded in 1996…

Valuation

Trailing twelve months. Multiples relative to current market price.
P/E (TTM)	-27.41×
P/S (TTM)	6.65×
P/B	0.82×
PEG	0.23×
P/FCF (TTM)	10.34×
EV / EBITDA	10.04×
EV / Sales	6.28×
Earnings Yield	-3.66%
Free Cash Flow Yield	9.67%
Dividend Yield	25.16%

Fundamentals

Trailing twelve months. Source: financial statements via market data.
Enterprise Value	$181.67M
Revenue (TTM)	$28.93M
Net Income (TTM)	-$7.03M
Free Cash Flow (TTM)	$16.88M
Net Debt	-$10.65M
Working Capital	$41.81M
Gross Margin	95.99%
Operating Margin	55.00%
Net Margin	-24.45%
Return on Equity	-2.88%
Return on Invested Capital	-2.94%